Literature DB >> 27178698

Cutaneous manifestations of nontargeted and targeted chemotherapies.

Veronica J Shi1, Lauren L Levy1, Jennifer N Choi2.   

Abstract

Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Cutaneous adverse reactions; Cytotoxic chemotherapy; Immunotherapy; Multikinase inhibitors; Targeted chemotherapy; Toxic erythema

Mesh:

Substances:

Year:  2016        PMID: 27178698     DOI: 10.1053/j.seminoncol.2016.02.018

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  Cutaneous Toxicities of Molecular Targeted Therapies.

Authors:  Dana Lucia Stanculeanu; Daniela Zob; Oana Catalina Toma; Bogdan Georgescu; Laura Papagheorghe; Raluca Ioana Mihaila
Journal:  Maedica (Bucur)       Date:  2017-01

Review 2.  New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury.

Authors:  Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

Review 3.  Targeting of epigenetic regulators in neuroblastoma.

Authors:  Luz Jubierre; Carlos Jiménez; Eric Rovira; Aroa Soriano; Constantino Sábado; Luis Gros; Anna Llort; Raquel Hladun; Josep Roma; Josep Sánchez de Toledo; Soledad Gallego; Miguel F Segura
Journal:  Exp Mol Med       Date:  2018-04-27       Impact factor: 8.718

4.  PI3K inhibitors protect against glucocorticoid-induced skin atrophy.

Authors:  Shivani Agarwal; Salida Mirzoeva; Ben Readhead; Joel T Dudley; Irina Budunova
Journal:  EBioMedicine       Date:  2019-02-05       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.